线粒体自噬受体Bnip3的载体构建及蛋白表达纯化

[目的]获得可用于蛋白晶体筛选的高纯度Bnip3蛋白。[方法]将Bnip3截断基因构建到原核表达载体上并转化大肠杆菌。IPTG诱导表达后通过GST柱纯化目标蛋白。TEV酶切除GST标签后采用凝胶过滤层析纯化Bnip3蛋白。[结果]Bnip3截断基因重组体成功构建并诱导表达目标蛋白。通过GST亲和层析得到可溶性的携带GST标签的Bnip3(1~111)和Bnip3(1~152)蛋白。切除GST标签的Bnip3(1~152)通过凝胶过滤层析得到构象均一的二聚体蛋白。[结论]采用原核表达、亲和层析和凝胶过滤层析可获得构象均一的高纯度二聚体Bnip3蛋白。     

铜绿假单胞菌LexA蛋白的纯化及免疫活性分析

目的：对铜绿假单胞菌(Pseudomonas aeruginosa,PA)的LexA蛋白进行表达、纯化,并检测其免疫活性。方法： lexA基因片段插入表达载体pET32a(+),在E.coli BL21(DE3)中表达。包涵体经洗涤并用8M尿素溶解,镍离子亲合柱层析为第一步纯化,Superdex 75凝胶过滤层析作为第二步精细纯化,HPLC测定蛋白的浓度,将纯化的LexA蛋白经注射途径免疫家兔,制备兔抗LexA血清,采用免疫双扩、ELISA及Western Blot分析LexA的免疫活性。结果：LexA以包涵体形式表达,经镍离子亲合柱层析和凝胶过滤层析二步组合纯化目的蛋白,经HPLC测定目的蛋白的最终纯度为98.97%,表达及纯化的LexA具有良好的免疫活性。     

NMDAR1蛋白膜外抗原结构域的重组表达、纯化和免疫反应原性鉴定

构建编码NMDAR1蛋白膜外片段的原核表达重组质粒,在大肠杆菌中诱导表达、纯化并鉴定其免疫反应原性。根据人NMDAR1基因序列,利用Phyre 2软件预测蛋白的三级结构并分析其结构域。设计引物用RT-PCR方法扩增编码NMDAR1膜外蛋白不同结构域的核酸片段,并插入原核表达载体pCold-SUMO构建重组质粒。转化DH5α感受态细胞,菌落PCR鉴定,阳性单克隆进行测序验证。鉴定正确的重组体转化大肠杆菌BL21(DE3),IPTG诱导目的蛋白的表达和纯化,Ni-NTA柱亲和层析和凝胶过滤层析纯化蛋白,酶切切除融合蛋白6His-SUMO标签,用AKTA Purifier进行凝胶过滤层析,收集纯化蛋白。利用SDS-PAGE鉴定蛋白纯度,并用Western blotting进行免疫反应性鉴定。克隆获得NMDAR1膜外部分的三段DNA序列,分别是NR1-M1(编码19–393 aa)、NR1-S1(编码394–544 aa)和NR1-S2(编码663–800 aa)。其中NR1-S1和NR1-S2片段之间以G(甘氨酸)和T(苏氨酸)作为接头连接成为复合片段。经菌落PCR筛选和测序鉴定,成功构建了重组质粒p Cold-SUMO-M1和p Cold-SUMO-S1-GT-S2。SDS-PAGE鉴定结果表明重组质粒在大肠杆菌中经诱导可表达可溶性NR1-M1及NR1-S1-GT-S2蛋白。对表达产物进行亲和层析和凝胶过滤层析获得了高纯度的目标蛋白。Western blotting证实纯化的目的蛋白能与相应抗体发生特异性结合反应。本研究成功构建了NMDAR1蛋白膜外抗原结构域的原核表达系统,并获得了具有免疫反应性的NR1-M1及NR1-S1-GT-S2纯化蛋白。该蛋白有望用于NMDAR1蛋白的功能研究及自身抗体的检测。     

直组人嗜中性白细胞活化蛋白-1/白细胞介素-8的纯化与鉴定

本文利用SDS-PAGE及蛋白质电泳印迹技术,从带有相应表达质粒的重组大肠杆菌裂解液中,将所表达的重组人嗜中性白细胞活化蛋白-1/白细胞介素-8(NAP-1/IL-8)转移至聚偏二氟乙烯膜上,直接进行N-末端15个氨基酸的序列分析,从而确证该目标蛋白得到高效表达和正确加工。随后采用Bio-Gel P30凝胶过滤层析和Mono-S阳离子交换层析对重组人NAP-1/IL-8进行了分离纯化,纯化产品达到SDS-PAGE纯。利用琼脂糖平板法测定了纯化产品的嗜中性白细胞趋化活性,推算其比活为2.8×10~5U/mg蛋白。又利用SDS-PAGE测出重组NAP-1/IL-8的分子量约为8.5kD,但根据凝胶过滤层析的洗脱时间推定,在溶液中确实存在分子量稍大于14.4kD的NAP-1/IL-8二聚体。     

重组人胰岛新生相关蛋白的表达、纯化及免疫活性研究

摘要 目的：对胰岛新生相关蛋白（Islet neogenesis associated protein ,INGAP）进行表达、纯化,并检测其免疫活性。方法： INGAP基因片段插入表达载体pET22b(+),在E.coli BL21(DE3)中表达。包涵体经洗涤并用8M尿素溶解,Heparin Agrose亲合柱层析为第一步纯化,Superdex75凝胶过滤层析作为第二步精细纯化,HPLC测定INGAP蛋白的浓度,将纯化的INGAP蛋白经注射途径免疫家兔,制备兔抗INGAP血清,采用免疫双扩、ELISA及Western Blot分析INGAP的免疫活性。结果INGAP以包涵体形式表达,表达产量高达总菌体蛋白的40%左右,经Heparin Agrose亲合柱层析和凝胶过滤层析二步组合纯化目的蛋白,经HPLC测定目的蛋白的最终纯度为98.81%,表达及纯化的INGAP具有良好的免疫活性。     

重组A型产气荚膜梭菌α毒素保护性抗原的制备及初步免疫保护作用研究

诱导表达重组工程菌Pbv/cpa408后,将表达菌体超声破碎,上清经80%饱和硫酸铵一次沉淀,经透析,上凝胶过滤层析柱进行分离纯化,薄层凝胶扫描结果显示,纯化的蛋白纯度达95%以上;用纯化蛋白免疫昆明小鼠,以1.0MLD100腹腔进行攻击,被免疫小鼠获得了100%的保护。     

Intein介导的重组昆虫毒素BmK IT在大肠杆菌中的可溶性表达、纯化及活性分析

为获得重组蝎昆虫毒素BmKIT,通过PCR方法在BmKIT基因的3′端融合了编码6个组氨酸残基的核苷酸序列,将其插入原核表达载体pTWIN1的内含肽Ssp DnaB Intein基因下游的多克隆位点(MCS)。将获得的表达质粒转化大肠杆菌BL21(DE3)中,用IPTG诱导融合蛋白表达。用Ni-NTA亲和层析柱从菌体裂解液中纯化了CBD-Intein-BmK IThis6融合蛋白,并在柱上诱导Intein自剪切,成功去除融合子CBD-Intein。通过Superdex75凝胶过滤层析获得了纯度达95%以上的BmK IThis6蛋白,该蛋白不仅具有正确的二级结构而且有生物活性。     

鼠疫耶尔森菌F1-V融合蛋白改构体的构建、原核表达及纯化

目的:通过基于结构的基因突变获得鼠疫耶尔森菌F1抗原突变体(F1mut),克隆、表达并纯化F1mut-V融合蛋白。方法:通过3轮PCR,将编码F1抗原分子N端1~14位氨基酸的基因序列移到3'端,测序无误后将F1mut基因与V基因的5'端连接,构建改构的融合基因F1mut-V,将其克隆到原核表达载体p ET-32a后转化大肠杆菌BL21(DE3),经IPTG诱导后,目的蛋白为可溶性表达,通过硫酸铵分级沉淀、阴离子交换层析、疏水相互作用层析和凝胶过滤层析纯化,用SDS-PAGE和Western印迹分析纯化产物。结果:重组F1mut-V在大肠杆菌中为可溶性表达,表达量占全菌蛋白的25%以上,纯化后目的蛋白的纯度达95%,经Western印迹检测,与抗V、F1抗体均有特异性结合。结论:重组F1mut-V有望成为新一代亚单位疫苗的有效成分。     

中华按蚊α-羧酸酯酶AsAe7的异源表达、纯化与结晶

【目的】羧酸酯酶(carboxylesterase,COE)是昆虫体内一类重要的解毒酶,与昆虫的抗药性相关。本研究旨在对中华按蚊Anopheles sinensis羧酸酯酶Ae7(Asae7)进行初步晶体学研究,为解析As Ae7的空间结构及探讨其分子功能奠定基础。【方法】首先对Asae7进行生物信息学分析,然后进行分子克隆,并利用原核表达系统在体外对Asae7进行重组表达;结合Ni-NTA金属螯合层析和葡聚糖凝胶层析方法纯化融合表达蛋白;通过葡聚糖凝胶层析和化学交联结果分析As Ae7的聚合状态;采用坐滴气相扩散法对As Ae7进行结晶筛选。【结果】生物信息学分析表明,As Ae7是亲水性蛋白,分子量为61.053 k D,无跨膜区和信号肽;3D结构预测结果分析显示,As Ae7采取的是α/β-水解酶超家族折叠模式。多序列比对结果表明,在不同昆虫中Ae7蛋白具有高度保守性。分子克隆得到中华按蚊As Ae7的编码基因Asae7序列,大小为1 626 bp。成功构建重组质粒p ET28aAsae7;在大肠杆菌Escherichia coli中表达的融合蛋白As Ae7主要分布在上清中。通过镍柱亲和层析和凝胶过滤层析纯化出了高纯度且稳定的目的蛋白;通过凝胶过滤层析和化学交联获得纯化的As Ae7主要呈单体状态;同时通过晶体筛选获得了As Ae7的晶体。【结论】运用结晶学的方法初步获得了As Ae7的晶体,为后续解析As Ae7的晶体结构以及在原子分辨率水平上直观阐释As Ae7参与代谢抗性的分子机制奠定了基础。     

效应蛋白LepB的表达,纯化及其亚克隆片段的结晶研究

为了研究嗜肺军团菌通过其效应蛋白发挥的致病机理,效应蛋白的结构和生物学功能研究是至关重要的。我们构建了效应蛋白LepB全长载体PFastBac1,应用Bac-to-Bac杆状病毒表达系统成功表达了全长LepB蛋白,并构建9个LepB亚克隆的原核表达载体PGEX-1,通过GST亲和层析,离子交换层析,凝胶过滤层析,纯化得到了纯度较高的蛋白片段。通过悬滴气相扩散法进行蛋白结晶筛选,获得了效应蛋白LepB片段480~679的蛋白晶体,为解析效应蛋白LepB的结构和生物学功能研究奠定基础。     

Stalk region of beta-chain enhances the coreceptor function of CD8

CD8 glycoproteins are expressed as either alphaalpha homodimers or alphabeta heterodimers on the surface of T cells. CD8alphabeta is a more efficient coreceptor than the CD8alphaalpha for peptide Ag recognition by TCR. Each CD8 subunit is composed of four structural domains, namely, Ig-like domain, stalk region, transmembrane region, and cytoplasmic domain. In an attempt to understand why CD8alphabeta is a better coreceptor than CD8alphaalpha, we engineered, expressed, and functionally tested a chimeric CD8alpha protein whose stalk region is replaced with that of CD8beta. We found that the beta stalk region enhances the coreceptor function of chimeric CD8alphaalpha to a level similar to that of CD8alphabeta. Surprisingly, the beta stalk region also restored functional activity to an inactive CD8alpha variant, carrying an Ala mutation at Arg(8) (R8A), to a level similar to that of wild-type CD8alphabeta. Using the R8A variant of CD8alpha, a panel of anti-CD8alpha Abs, and three MHC class I (MHCI) variants differing in key residues known to be involved in CD8alpha interaction, we show that the introduction of the CD8beta stalk leads to a different topology of the CD8alpha-MHCI complex without altering the overall structure of the Ig-like domain of CD8alpha or causing the MHCI to employ different residues to interact with the CD8alpha Ig domain. Our results show that the stalk region of CD8beta is capable of fine-tuning the coreceptor function of CD8 proteins as a coreceptor, possibly due to its distinct protein structure, smaller physical size and the unique glycan adducts associated with this region.     

CD8 Raft localization is induced by its assembly into CD8alpha beta heterodimers, Not CD8alpha alpha homodimers

The coreceptor CD8 is expressed as a CD8alphabeta heterodimer on major histocompatibility complex class I-restricted TCRalphabeta T cells, and as a CD8alphaalpha homodimer on subsets of memory T cells, intraepithelial lymphocytes, natural killer cells, and dendritic cells. Although the role of CD8alphaalpha is not well understood, it is increasingly clear that this protein is not a functional homologue of CD8alphabeta. On major histocompatibility complex class I-restricted T cells, CD8alphabeta is a more efficient TCR coreceptor than CD8alphaalpha. This property has for the mouse protein been attributed to the recruitment of CD8alphabeta into lipid rafts, which is dependent on CD8beta palmitoylation. Here, these divergent distributions of CD8alphabeta and CD8alphaalpha are demonstrated for the human CD8 proteins as well. However, although palmitoylation of both CD8alpha and CD8beta chains was detected, this modification did not contribute to raft localization. In contrast, arginines in the cytoplasmic domain are crucial for raft localization of CD8betabeta. Most strikingly, the assembly of a non-raft localized CD8beta chain with a non-raft localized CD8alpha chain resulted in raft-localized CD8alphabeta heterodimers. Using chimeric CD8 proteins, this property of the heterodimer was found to be determined by the assembly of CD8alpha and CD8beta extracellular regions. The presence of two CD8alpha extracellular regions, on the other hand, appears to preclude raft localization. Thus, heterodimer formation and raft association are intimately linked for CD8alphabeta. These results emphasize that lipid raft localization is a key feature of human CD8alphabeta that clearly distinguishes it from CD8alphaalpha.     

CD8alphabeta has two distinct binding modes of interaction with peptide-major histocompatibility complex class I

Interaction of CD8 (CD8alphaalpha or CD8alphabeta) with the peptide-major histocompatibility complex (MHC) class I (pMHCI) is critical for the development and function of cytolytic T cells. Although the crystal structure of CD8alphaalpha.pMHCI complex revealed that two symmetric CD8alpha subunits interact with pMHCI asymmetrically, with one subunit engaged in more extensive interaction than the other, the details of the interaction between the CD8alphabeta heterodimer and pMHCI remained unknown. The Ig-like domains of mouse CD8alphabeta and CD8alphaalpha are similar in the size, shape, and surface electrostatic potential of their pMHCI-binding regions, suggesting that their interactions with pMHCI could be very similar. Indeed, we found that the CD8alpha variants CD8alpha(R8A) and CD8alpha(E27A), which were functionally inactive as homodimers, could form an active co-receptor with wild-type (WT) CD8beta as a CD8alpha(R8A)beta or CD8alpha(E27A)beta heterodimer. We also identified CD8beta variants that could form active receptors with WT CD8alpha but not with CD8alpha(R8A). This observation is consistent with the notion that the CD8beta subunit may replace either CD8alpha subunit in CD8alphaalpha.pMHCI complex. In addition, we showed that both anti-CD8alpha and anti-CD8beta antibodies were unable to completely block the co-receptor activity of WT CD8alphabeta. We propose that CD8alphabeta binds to pMHCI in at least two distinguishable orientations.     

Molecular basis for the high affinity interaction between the thymic leukemia antigen and the CD8alphaalpha molecule

The mouse thymic leukemia (TL) Ag is a nonclassical MHC class I molecule that binds with higher affinity to CD8alphaalpha than CD8alphabeta. The interaction of CD8alphaalpha with TL is important for lymphocyte regulation in the intestine. Therefore, we studied the molecular basis for TL Ag binding to CD8alphaalpha. The stronger affinity of the TL Ag for CD8alphaalpha is largely mediated by three amino acids on exposed loops of the conserved alpha3 domain. Mutant classical class I molecules substituted with TL Ag amino acids at these positions mimic the ability to interact with CD8alphaalpha and modulate lymphocyte function. These data indicate that small changes in the alpha3 domain of class I molecules potentially can have profound physiologic consequences.     

Expression, purification, and functional analysis of murine ectodomain fragments of CD8alphaalpha and CD8alphabeta dimers.

Soluble mouse CD8alphaalpha and CD8alphabeta dimers corresponding to the paired ectodomains (CD8(f)) or their respective component Ig-like domains (CD8) were expressed in Chinese hamster ovary cells or the glycosylation variant Lec3.2.8.1 cells as secreted proteins using a leucine zipper strategy. The affinity of CD8alphaalpha(f) for H-2K(b) as measured by BIAcore revealed a approximately 65 microM K(d), similar to that of CD8alphabeta(f). Consistent with this result, CD8alphaalpha(f) as well as CD8alphabeta(f) blocked the effector function of N15 T cell receptor transgenic cytolytic T cells in a comparable, dose-dependent fashion. Furthermore, both Lec3.2.8.1-produced and Chinese hamster ovary-produced CD8 homodimers and heterodimers were active in the inhibition assay. These results suggest that the Ig-like domains of CD8 molecules are themselves sufficient to block the requisite transmembrane CD8-pMHC interaction between cytolytic T lymphocytes and target cells. Moreover, given the similarities in co-receptor affinities for pMHC, the findings suggest that the greater efficiency of CD8alphabeta versus CD8alphaalpha co-receptor function on T cells is linked to differences within their membrane-bound stalk regions and/or intracellular segments. As recently shown for sCD8alphaalpha, the yield, purity and homogeneity of the deglycosylated protein resulting from this expression system is sufficient for crystallization and x-ray diffraction at atomic resolution.     

Classical and nonclassical class I major histocompatibility complex molecules exhibit subtle conformational differences that affect binding to CD8alphaalpha

The cell surface molecules CD4 and CD8 greatly enhance the sensitivity of T-cell antigen recognition, acting as "co-receptors" by binding to the same major histocompatibility complex (MHC) molecules as the T-cell receptor (TCR). Here we use surface plasmon resonance to study the binding of CD8alphaalpha to class I MHC molecules. CD8alphaalpha bound the classical MHC molecules HLA-A*0201, -A*1101, -B*3501, and -C*0702 with dissociation constants (K(d)) of 90-220 microm, a range of affinities distinctly lower than that of TCR/peptide-MHC interaction. We suggest such affinities apply to most CD8alphaalpha/classical class I MHC interactions and may be optimal for T-cell recognition. In contrast, CD8alphaalpha bound both HLA-A*6801 and B*4801 with a significantly lower affinity (>/=1 mm), consistent with the finding that interactions with these alleles are unable to mediate cell-cell adhesion. Interestingly, CD8alphaalpha bound normally to the nonclassical MHC molecule HLA-G (K(d) approximately 150 microm), but only weakly to the natural killer cell receptor ligand HLA-E (K(d) >/= 1 mm). Site-directed mutagenesis experiments revealed that variation in CD8alphaalpha binding affinity can be explained by amino acid differences within the alpha3 domain. Taken together with crystallographic studies, these results indicate that subtle conformational changes in the solvent exposed alpha3 domain loop (residues 223-229) can account for the differential ability of both classical and nonclassical class I MHC molecules to bind CD8.     

The complementarity-determining region-like loops of CD8 alpha interact differently with beta 2-microglobulin of the class I molecules H-2Kb and thymic leukemia antigen, while similarly with their alpha 3 domains

The murine CD8 glycoprotein interacts with both classical MHC class I molecules and some nonclassical molecules, including the thymic leukemia Ag (TL). TL binds preferentially to CD8alphaalpha homodimers with a 10-fold higher affinity than H-2K(b) class I molecules. To understand the molecular basis for this difference, we created a panel of CD8alpha mutants and tested the ability of the CD8alphaalpha homodimers to bind to H-2K(b) tetramers and TL tetramers. Mutations in three CD8 residues located on the complementarity-determining region-like loops contacting the negatively charged loop in the alpha3 domain of MHC class I greatly reduced binding to both tetramers. Because TL and H-2K(b) class I sequences are highly conserved in the alpha3 domain of MHC class I, this suggests that CD8 contacts the alpha3 domain of TL and H-2K(b) in a similar manner. In contrast, mutations in residues on the A and B beta strands of CD8 that are involved in contact with beta(2)-microglobulin affected interaction with the H-2K(b) tetramer, but not the TL tetramer. Therefore, the orientation of interaction of TL with CD8 appears to be different from that of H-2K(b). The unique high affinity binding of TL with CD8alphaalpha is most likely a result of amino acid differences in the alpha3 domain between TL and H-2K(b), particularly at positions 198 (K to D) and 228 (M to T), which are contact residues in the CD8alphaalpha-H-2K(b) cocrystal.     

Crystal structure of the TCR co-receptor CD8alphaalpha in complex with monoclonal antibody YTS 105.18 Fab fragment at 2.88 A resolution

The CD8 glycoprotein functions as an essential element in the control of T-cell selection, maturation and the TCR-mediated response to peptide antigen. CD8 is expressed as both heterodimeric CD8alphabeta and homodimeric CD8alphaalpha isoforms, which have distinct physiological roles and exhibit tissue-specific expression patterns. CD8alphaalpha has previously been crystallized in complex with class I pMHC and, more recently, with the mouse class Ib thymic leukemia antigen (TL). Here, we present the crystal structure of a soluble form of mouse CD8alphaalpha in complex with rat monoclonal antibody YTS 105.18 Fab fragment at 2.88 A resolution. YTS 105.18, which is commonly used in the blockade of CD8+ T-cell activation in response to peptide antigen, is specific for mouse CD8alpha. The YTS 105.18 Fab is one of only five rat IgG Fab structures to have been reported to date. Analysis of the YTS 105.18 Fab epitope on CD8alpha reveals that this antibody blocks CD8 activity by hydrogen bonding to residues that are critical for interaction with both class I pMHC and TL. Structural comparison of the liganded and unliganded forms of soluble CD8alphaalpha indicates that the mouse CD8alphaalpha immunoglobulin-domain dimer does not undergo significant structural alteration upon interaction either with class I pMHC or TL.     

Computational design and crystal structure of an enhanced affinity mutant human CD8 alphaalpha coreceptor

Human CD8 is a T cell coreceptor, which binds to pHLA I and plays a pivotal role in the activation of cytotoxic T lymphocytes. Soluble recombinant CD8 alphaalpha has been shown to antagonize T cell activation, both in vitro and in vivo. However, because of a very low affinity for pHLA I, high concentrations of soluble CD8 alphaalpha are required for efficient inhibition. Based upon our knowledge of the wild-type CD8/pHLA I structure, we have designed and produced a mutated form of soluble CD8 alphaalpha that binds to pHLA I with approximately fourfold higher affinity. We have characterized the binding of the high affinity CD8 mutant using surface plasmon resonance and determined its structure at 2.1 A resolution using X-ray crystallography. The analysis of this structure suggests that the higher affinity is achieved by providing a larger side chain that allows for an optimal contact to be made between the HLA alpha3 loop and the mutated CDR-like loops of CD8.     

Mapping the binding site on CD8 beta for MHC class I reveals mutants with enhanced binding

In an effective immune response, CD8+ T cell recognition of virally derived Ag, bound to MHC class I, results in killing of infected cells. The CD8alphabeta heterodimer acts as a coreceptor with the TCR, to enhance sensitivity of the T cells to peptide/MHC class I, and is two orders of magnitude more efficient as a coreceptor than the CD8alphaalpha. To understand the important interaction between CD8alphabeta and MHC class I, we created a panel of CD8beta mutants and identified mutations in the CDR1, CDR2, and CDR3 loops that decreased binding to MHC class I tetramers as well as mutations that enhanced binding. We tested the coreceptor function of a subset of reducing and enhancing mutants using a T cell hybridoma and found similar reducing and enhancing effects. CD8beta-enhancing mutants could be useful for immunotherapy by transduction into T cells to enhance T cell responses against weak Ags such as those expressed by tumors. We also addressed the question of the orientation of CD8alphabeta with MHC class I using CD8alpha mutants expressed as a heterodimer with wild-type CD8alpha or CD8beta. The partial rescuing of binding with wild-type CD8beta compared with wild-type CD8alpha is consistent with models in which either the topology of CD8alphaalpha and CD8alphabeta binding to MHC class I is different or CD8alphabeta is capable of binding in both the T cell membrane proximal and distal positions.